⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073974 | 0.73 | — | — | |
| SCHEMBL17599039 | 0.72 | — | — | |
| SCHEMBL4967269 | 0.72 | — | — | |
| SCHEMBL9864095 | 0.72 | — | — | |
| SCHEMBL601273 | 0.71 | — | — | |
| SCHEMBL4031160 | 0.71 | — | — | |
| SCHEMBL5076455 | 0.71 | — | — | |
| SCHEMBL964277 | 0.71 | — | — | |
| SCHEMBL1227367 | 0.71 | — | — | |
| SCHEMBL1030802 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120476-A | Antibodies specific for structurally disordered sequences | XL-普洛坦公司 | 2023-11-24 | — | — | CN | claimed |
| EP-4267628-A1 | ANTIBODIES SPECIFIC FOR STRUCTURALLY DISORDERED SEQUENCES | XL-protein GmbH (DE) | 2023-11-01 | — | — | EP | claimed |
| WO-2022136582-A1 | ANTIBODIES SPECIFIC FOR STRUCTURALLY DISORDERED SEQUENCES | XL-PROTEIN GMBH (DE) | 2022-06-30 | — | — | WO | claimed |
| US-20200282071-A1 | CONJUGATES OF PROTEIN DRUGS AND P/A PEPTIDES | XL-PROTEIN GMBH (DE) | 2020-09-10 | — | — | US | claimed |
| EP-3641827-A1 | CONJUGATES OF PROTEIN DRUGS AND P/A PEPTIDES | XL-protein GmbH (DE) | 2020-04-29 | — | — | EP | claimed |
| CN-110891612-A | Conjugates of protein drugs and P/A peptides | XL-蛋白有限责任公司 | 2020-03-17 | — | — | CN | claimed |
| WO-2018234455-A1 | CONJUGATES OF PROTEIN DRUGS AND P/A PEPTIDES | XL-PROTEIN GMBH (DE) | 2018-12-27 | — | — | WO | claimed |
| CN-117120476-A | Antibodies specific for structurally disordered sequences | XL-普洛坦公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| EP-4267628-A1 | ANTIBODIES SPECIFIC FOR STRUCTURALLY DISORDERED SEQUENCES | XL-protein GmbH (DE) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136582-A1 | ANTIBODIES SPECIFIC FOR STRUCTURALLY DISORDERED SEQUENCES | XL-PROTEIN GMBH (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20210309619-A1 | ISOXAZOLIN-5-ONE DERIVATIVES AND HERBICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2021-10-07 | — | — | US | disclosed |
| US-11109593-B2 | Isoxazolin-5-one derivative and herbicide containing same as active ingredient | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2021-09-07 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-0820441-B1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
| US-6358992-B1 | Method of inhibiting neoplastic cells with indole derivatives | CELL PATHWAYS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6069156-A | Indole derivatives as cGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0820441-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032379-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-17 | — | — | WO | disclosed |